Five points on CMS’s first ten picks for price negotiations
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Both JANUVIA® and Jardiance® are covered as Tier 3 preferred brands on more than 70% of formularies.
Let's personalize your content